Novartis 3Q Revenues: $12.3 billion (+1%) 3Q Earnings: $1.9 billion (-5%) YTD Revenues: $35.9 billion (+2 %) YTD Earnings: $6.0 billion (-44%) Comments: Growth drivers in the quarter included Entresto $632 million (+45% cc), Zolgensma $291 million (+79% cc), Cosentyx $1.0 billion (+7% cc), Kisqali $183 million (+50% cc) and Promacta/Revolade $442 million (+16% cc). Sandoz Biopharmaceuticals grew 13% with growth across all regions. Innovative Medicines sales were $9.8 billion ...